# Phase II Proof-of-concept Study of APD421

> **NCT01303978** · PHASE2 · COMPLETED · sponsor: **Acacia Pharma Ltd** · enrollment: 51 (actual)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** APD421

## Key facts

- **NCT ID:** NCT01303978
- **Lead sponsor:** Acacia Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2012-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01303978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01303978, "Phase II Proof-of-concept Study of APD421". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01303978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*